A Pilot Study Evaluating a Novel Magneto-Fluidic System for Ultra-High Throughput Detection of Circulating Tumor Cells in Patients with Metastatic and Loco-regional Urothelial Bladder Cancer IUSCC-0552
Hristos Kaimakliotis, MD
Primary Investigator
Overview
The purpose of this study is to determine if cancer cells in blood can be reliably detected in bladder cancer patients using a new blood test known as a "liquid biopsy."
Description
The purpose of this study is to test and optimize this magneto-fluidic system we have developed to capture circulating tumor cells from samples of patients with advanced urothelial bladder cancer, and potentially applu this system to an earlier clinical stage cohort to predict advanced pathology.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
bladder cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
Patients must have histologically confirmed advanced urothelial bladder cancer, specifically metastatic or muscle invasive disease
Previously untreated patients and patients with prior therapies will be allowed as long as therapy was give > or = 3 weeks prior to blood collection